Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Mirvetuximab Soravtansine (Elahere)

decorative image of the issue cover

Published October 29, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Elahere be reimbursed by public drug plans for the treatment of adults with FR-alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens if certain conditions are met.
  • Elahere should only be covered to treat patients with a confirmed diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer who have platinum-resistant disease, a tumour that is positive for FR-alpha expression confirmed by a validated test, disease that progressed on or after their most recent line of therapy, and received at least 1 prior systemic line of anticancer therapy.
  • Elahere should only be reimbursed if the patient is under the care of a physician with expertise in managing gynecological malignancies, if the treatment is administered in an oncology health facility with access to ophthalmic services and FR-alpha testing, and if the cost of Elahere is reduced.